Atlas Trials

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

Clinical trial NCT03464916 · COMPLETED

Trial details

NCT number
NCT03464916
Sponsor
Sorrento Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed or Refractory Multiple Myeloma
Start date
2018-10-15
Primary completion
2020-08-23
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.